John Potthoff

John Potthoff, PhD is a respected veteran with over 26 years in the clinical research services industry. Potthoff’s career began with a series of executive roles managing clinical trials with PPD. After seven years, he became the founder and CEO of Tanistry, Inc., a CRO focused on central nervous system clinical trials. After selling Tanistry to INC Research in 2001, he joined INC Research, a career step that culminated in the role of COO and included seven acquisitions and the sale of the company to PE investors in 2010. Following his success at INC Research, Potthoff assumed the position of CEO at Theorem Clinical Research in 2011. In four years, he doubled its revenue, sales, backlog, and earnings.

The theorem was sold to Chiltern International in 2015, resulting in a record ROI for its PE owner. Potthoff remained as a member of the board of directors for Chiltern until its sale to Covance/LabCorp. Potthoff is currently co-founder and CEO of Elligo Health Research – providing physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Additionally, Potthoff serves on the board of directors of Synteract and Chembio Diagnostics (CEMI), and, previously served on the board of directors for Advarra. He earned his PhD at the University of Texas.